Assessment of nootropic drug assortment in the pharmaceutical sector of Uzbekistan

Background. Nootropics are pharmacological agents that enhance such cognitive functions as memory and attention, as well as the overall mental performance. In recent years, global demand for these pharmaceuticals has significantly increased due to intensified psychological stress, a growing incidence of neurological disorders, and a growing public focus on mental health. In Uzbekistan, the nootropic drug market is experiencing active growth, underscoring the need for a comprehensive analysis of its structure and key trends.

Objective: To analyze trends in the nootropic drug market in Uzbekistan from 2015 to 2024, to identify key trends and factors influencing its development, and to assess the dynamics of supply and demand.

Material and methods. The available data on registered nootropic drugs in Uzbekistan, pharmaceutical company reports, sales statistics, and information on government policy and support measures were used. The dynamics of the number of registered trade names and their distribution by manufacturing country were studied. Leading companies playing a key role in the market were identified. The distribution of nootropics by composition (monodrugs and combination forms) and dosage forms (oral, injectable, etc.) was also examined.

Results. The analysis revealed a steady growth in the nootropic drug market in Uzbekistan throughout the study period. This growth is primarily driven by the increasing demand for cognitive enhancers across various age groups. One evident trend consists in the expanding presence of domestic manufacturers, who are introducing novel drug forms, including combination and injectable formulations. Additionally, innovative compounds, such as citicoline that has shown considerable therapeutic potential across various neurological conditions, are increasingly attracting attention.

Conclusion. The nootropic drug market in Uzbekistan is demonstrating positive growth dynamics, driven by rising consumer demand and reinforced by supportive government initiatives. The market is expected to continue to grow, with improvements in drug variety and accessibility. Both local and international pharmaceutical companies play a pivotal role in enhancing product quality and ensuring broad patient access.

1. Yao M., Ren Y., Jia Y., et al. Projected burden of stroke in China through 2050. Chin Med J. 2022; 136: 1598–605. https://doi.org/10.1097/CM9.0000000000002060.

2. Vos T., Lim S.S., Abbafati C., et al. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396 (10258): 1204–22. https://doi.org/10.1016/S01406736(20)30925-9.

3. World Life Expectancy. World rankings. Total deaths. Available at: https://www.worldlifeexpectancy.com/world-rankings-total-deaths (accessed 06.11.2025).

4. Kotvytskaya A.A., Lobova I.O. Assessment of the epidemiological status of cerebrovascular diseases among the population of Ukraine and ways to improve it. Management, Economy and Quality in Pharmacy. 2013; 2: 74–80 (in Ukranian).

5. Kovalchuk V.V. Cognitive dysfunction. A modern view of etiology, pathogenesis, diagnostics and therapy. Effektivnaya farmakoterapiya / Effective Pharmacotherapy. 2020; 16 (31): 40–52 (in Russ.).

6. Norvina T.S., Ochirova A.D., Romanyuk S.V. The influence of nootropic drugs on the mental activity of students. In: Sukiasyan А.А. (Ed.) Society, intelligence, initiative in the context of interdisciplinary research: a collection of articles from the International Scientific and Practical Conference. Sterlitamak: Agency for International Research; 2023: 30–3 (in Russ.).

7. Burchinskiy S.G., Gonchar A.Yu., Raychenko K.V. The problem of nootropic pharmacotherapy safety in neurological practice. International Neurological Journal. 2017; 7: 56–60 (in Russ.).

8. Mishchenko O.Ya., Palagina N.Yu., Khaleeva O.L., Greshko Yu.I. Analysis of the assortment and economic affordability of noоtropic drugs. Social Pharmacy in Health Care. 2021; 7 (1): 80–6 (in Ukranian).

9. Polkovnikova Y.A., Dzuba V.Ph., Tulskaya U.A. Study of stability of capsules of vinpocetine. Proceedings of Voronezh State University. Series: Chemistry. Biology. Pharmacy. 2015; 3: 120–3 (in Russ.).

10. Belozertsev Yu.A. Fundamentals of evidence-based pharmacology: lecture course. 5th ed. Chita: Chita State Medical Academy; 2021: 47–52 (in Russ.).

11. Dimitrieva S.V., Fakhme F.A. Nootropics and vasoactive drugs in the clinical practice of a neurologist. In: Zakharova A.N. (Ed.) Collection of scientific papers of young scientists and specialists. Cheboksary: Chuvash State University named after. I.N. Ulyanova; 2022: 314–7 (in Russ.).

12. Shogenov B.Yu., Kumakhova D.B. The effect of stress on a person. Economy and Society. 2020; 1: 917–29 (in Russ.).

13. Kabanok K.V., Gatsan V.V. Marketing analysis of the assortment of local anesthetics. Modern Problems of Science and Education. 2015; 2-2: 490 (in Russ.).

14. Umarova Sh.Z., Sultanbaeva N.M.U. Optimization of systemic pharmaceutical care for patients with cardiovascular diseases: monograph. Tashkent; 2020.

15. Molchan A.V., Kovner O.V. Marketing research of the range of medicinal preparations of the nootropics group. In: Tolstenok I.V. (Eds) Current issues in modern medicine: proceedings of the 6th Far Eastern Medical Youth Forum. Khabarovsk: Far Eastern State Medical University; 2022: 265–7 (in Russ.).